-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
VV116
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/vv116.gif)
| Category | Influenza Virus |
| Description | VV116 (JT001) is an orally active nucleoside antiviral agent against SARS-CoV-2 and respiratory syncytial virus (RSV) infection. VV116 has favorable oral bioavailability, excellent in vitro antiviral activity and selectivity. |
Product Information
| Synonyms | VV116|GTPL11993|JT001|VV-116|X6 hydrobromide [PMID: 34584244] |
| Molecular Weight | 583.45 |
| Molecular Formula | C24H31N5O7 |
| Canonical SMILES | CC(C)C(=O)OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)OC(=O)C(C)C)OC(=O)C(C)C |
| Purity | 99.37% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to light yellow (Solid) |
| Storage | 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture) |
| Complexity | 887 |
| Exact Mass | 502.22862509 |
| In Vitro | VV116 (0-1000 μM; 48 hours) can inhibit RSV replication in A549 cells. |
| In Vivo | VV116 (25, 50 and 100 mg/kg; PO; b.i.d for 4 days) exhibits a stronger activity and decreases the virus titers below the detection limit at 50 mg/kg, also reduces lung injury after RSV infection. VV116 (25, 50 and 100 mg/kg; PO; single dosage) exhibits favorable PK properties and good safety profile. |
| Target | SARS-CoV; RSV; Influenza Virus |
| XLogP3-AA | 2.3 |
